Accessibility Menu
Harvard Bioscience logo

Harvard Bioscience(NASDAQ) HBIO

Market Cap$34.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2000)-91%
5 Year-91%
1 Year+51%
1 Month+26%
$7.58
+0.40%
+0.03Today
Harvard Bioscience last closing stock price
MetricPriceDate
Last closeUSD 7.582026-08-25
Harvard Bioscience stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week+8.75%USD 6.972026-08-18
1 month+26.33%USD 6.002026-07-24
3 month+31.14%USD 5.782026-05-27
Year to date+13.34%USD 6.692025-12-31
1 year+51%USD 5.022025-08-25
3 year-82.41%USD 43.102023-08-25
5 year-90.69%USD 81.402021-08-26
Since inception-90.51%USD 79.552000-12-07

Harvard Bioscience Financials at a Glance

Market Cap

$34.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

$87.81M

Net Income (TTM)

-$10.41M

EPS (TTM)

-$2.32

P/E Ratio

-3.26

Dividend

$0.00

Beta (Volatility)

1.38 (Average)

Price

$7.58

Volume

6,055.538

Open

$7.36

Previous Close

$7.58

Daily Range

$7.36 - $7.58

52-Week Range

$3.76 - $9.40

Estimated Earnings Date

Nov 5, 2026

HBIO News

Foolcom-Featured.png

Harvard Bioscience Tops Q2 Revenue Views

Motley Fool Markets TeamAug 11, 2025
invitae

Why Harvard Bioscience Stock Rose This Week

James HalleyApr 27, 2023

I’m Selling Harvard Biosciences

Jim RoyalMar 27, 2014

Why Harvard Bioscience Is Poised to Pop

BRIAN PACAMPARAJan 22, 2013

I'm Putting Real Money on Harvard Bioscience

Jim RoyalJan 18, 2013

Here's How Harvard Bioscience May Be Failing You

Seth JaysonAug 1, 2011

5-Star Stocks Poised to Pop: Harvard Bioscience

BRIAN PACAMPARAApr 26, 2011

Tomorrow's Monster Stock?

Rich DupreyMar 31, 2011
Page 1

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Harvard Bioscience

Harvard Bioscience, Inc. is a global innovator in life sciences technologies that support research, drug discovery, and bioproduction. With operations in the United States, Europe, and China, the company caters to a diverse customer base, including academic institutions and pharmaceutical companies.

Products and Services

Cellular and Molecular Technologies (CMT) for supporting academic research and drug development.

Preclinical products aiding in physiological data assessment for drug discovery and development.

Electroporation and electrofusion systems for bioproduction applications.

Telemetry systems for data collection in high-density environments.

Analytical instrumentation like spectrophotometers and amino acid analyzers.

What Makes Harvard Bioscience, Inc. Special

Harvard Bioscience stands out through its commitment to innovation in life sciences instrumentation. By focusing on cutting-edge solutions and maintaining a diverse product portfolio, the company ensures steady demand across multiple market segments, thereby enhancing its resilience and competitive edge.

Five Things You Need to Know

Founded in 1901, it has a strong historical foundation in life sciences research tools.

Approximately 49% of sales come from the CMT product family, with preclinical products contributing 51%.

The company's strategic goal includes expanding organoid research for advancements in neurological and cardiac research.

It has a diverse customer base including pharmaceutical giants like Pfizer and academic institutions such as Harvard University.

Sales are a mix of direct sales and distributor networks, accounting for 63% and 37% of revenues respectively in 2024.

AI Generated • Apr 16, 2026

Industry

Life Sciences Tools and Services

Sector

Health Care

Employees

339

CEO

John D. Duke, MBA

Website

www.harvardbioscience.com

Headquarters

Holliston, MA 01746, US

HBIO Financials

Key Financial Metrics (TTM)

Gross Margin

58.16%

Operating Margin

1.17%

Net Income Margin

-11.86%

Return on Equity

-92.01%

Return on Capital

-1.08%

Return on Assets

-13.65%

Earnings Yield

-30.67%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$34.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

4.55M

Volume

6.06K

Avg. Volume

19.02K

Financials (TTM)

Gross Profit

$51.07M

Operating Income

$1.03M

EBITDA

-$939.00K

Operating Cash Flow

$649.00K

Capital Expenditure

-$2.06M

Free Cash Flow

-$1.41M

Cash & ST Invst.

$6.50M

Total Debt

$44.21M

Harvard Bioscience Performance Analysis

Harvard Bioscience annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31USD 113,335,000-4.7%
20232023-12-31USD 112,250,000-1.0%
20242024-12-31USD 94,135,000-16.1%
20252025-12-31USD 86,550,000-8.1%
Harvard Bioscience sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-300.7%
Q42025-12-3115.3%
Q12026-03-31-12.6%
Q22026-06-309.5%
Harvard Bioscience annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31USD -2.303118.2%
20232023-12-31USD -0.81-65.0%
20242024-12-31USD -2.85253.9%
20252025-12-31USD -12.77348.3%
Harvard Bioscience sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-3046.4%
Q42025-12-31-131.9%
Q12026-03-31-20.3%
Q22026-06-3016.9%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

$22.73M

+11.1%

Gross Profit

$12.63M

+21.8%

Gross Margin

55.57%

N/A

Market Cap

$34.51MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$105.20K

N/A

Employees

328

N/A

Net Income

-$2.91M

-27.5%

EBITDA

$1.09M

+600.6%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

$6.50M

-12.6%

Total Debt

$44.21M

+2.1%

Accounts Receivable

$14.50M

+21.5%

Inventory

$22.23M

-0.1%

Long Term Debt

$42.61M

+508.9%

Short Term Debt

$1.60M

-95.6%

Return on Assets

-13.65%

N/A

Return on Invested Capital

1.99%

N/A

Free Cash Flow

-$365.00K

-114.5%

Operating Cash Flow

$323.00K

-88.3%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
TAOXTAO Synergies Inc.
$3.95+1.02%
COSMCosmos Health Inc.
$0.21-0.58%
NCNANuCana plc
$1.47-0.68%
FEMYFemasys Inc.
$2.85-4.36%

Trending Stocks

Symbol / CompanyPricePrice Chg
NVDANvidia
$213.05+0.02%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.09+0.01%
INTCIntel
$87.48+0.00%
BITOProShares Trust - ProShares Bitcoin ETF
$10.66+0.00%

Questions About HBIO

What is the current price of Harvard Bioscience?

Harvard Bioscience is trading at $7.58 per share.

What is the 52-week range for Harvard Bioscience?

Over the past 52 weeks, Harvard Bioscience has traded between $3.76 and $9.40.

How much debt does Harvard Bioscience have?

As of the most recent reporting period, Harvard Bioscience reported total debt of $44.21M.

How much cash does Harvard Bioscience have on hand?

Harvard Bioscience reported $6.50M in cash and cash equivalents in its most recent financial results.

What is Harvard Bioscience’s dividend yield?

Harvard Bioscience does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services